WHO ICTRP trial
Effect of Linagliptin and Empagliflozine on diabetes
IRCT20221016056201N1 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20221016056201N1 |
|---|---|
| Public title | Effect of Linagliptin and Empagliflozine on diabetes |
| Scientific title | Evaluation the effect of Linagliptin and Empagliflozin combination on glycosylated hemoglobin and fasting blood sugar control in patients with type 2 diabetes |
| Primary sponsor | Arak University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 2 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Diabetes type 2. Type 2 diabetes mellitus |
| Interventions | Intervention group: type 2 diabetic patients resistant to other oral anti-diabetic treatments (metformin, glybenclamide and acarbose) whose FBS and HbA1C are not within the therapeutic range despite regular use of these drugs. These… |
| Registration date | Feb 8, 2023 |
| Target size | 55 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: